Korro Bio Company
OPERA™ platform using oligonucleotides to make precise, single-base edits to RNA; a modality-focused company.
Connections from
Total Funding:
> $200 M (Public via merger)
Last Funding Type:
Series A
Founded Date:
2018
Industry:
PharmTech
Employee Number:
11-50
Funding Status:
Early Stage Venture
Headquarters:
USA